FreeQAs
 Request Exam  Contact
  • Home
  • View All Exams
  • New QA's
  • Upload
PRACTICE EXAMS:
  • Oracle
  • Fortinet
  • Juniper
  • Microsoft
  • Cisco
  • Citrix
  • CompTIA
  • VMware
  • SAP
  • EMC
  • PMI
  • HP
  • Salesforce
  • Other
  • Oracle
    Oracle
  • Fortinet
    Fortinet
  • Juniper
    Juniper
  • Microsoft
    Microsoft
  • Cisco
    Cisco
  • Citrix
    Citrix
  • CompTIA
    CompTIA
  • VMware
    VMware
  • SAP
    SAP
  • EMC
    EMC
  • PMI
    PMI
  • HP
    HP
  • Salesforce
    Salesforce
  1. Home
  2. SOCRA Certification
  3. CCRP Exam
  4. SOCRA.CCRP.v2025-12-08.q47 Dumps
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • »
  • »»
Download Now

Question 1

In accordance with 45 CFR 46, in addition to the Office for Human Research Protections (OHRP), a suspension of IRB/IEC approval must be reported to which of the following?

Correct Answer: B
If IRB/IEC approval is suspended or terminated, reporting is required to protect oversight and accountability.
* 45 CFR 46.113:"An IRB shall notify theinstitutional officials, the department or agency head, and OHRP(when applicable) of any suspension or termination of IRB approval." This ensures transparency and institutional responsibility for compliance. Internal hospital committees or directors (A, C, D) are not mandated reporting entities.
Thus, the correct answer isB (Appropriate institutional officials).
References:
45 CFR 46.113 (Suspension or termination of IRB approval).
insert code

Question 2

The sponsor of a multi-institutional clinical trial provided a site with information regarding a newly identified unanticipated adverse event attributed to study drug administration. The site's investigator has a subject actively receiving this study drug. Which of the following is the site investigator's responsibility to the subject?

Correct Answer: C
Investigators are obligated to inform subjects ofnew informationthat may affect their willingness to continue.
* ICH E6(R2) 4.8.2:"If new information becomes available that may be relevant to a subject's willingness to continue participation, the informed consent document should be revised, and the subject should be informed in a timely manner."
* 21 CFR 50.25(b)(5):Consent must include a statement that "significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided." Thus, the investigator mustcommunicate new risk information to the subject.
Discontinuation (A) may not be warranted unless medically indicated. Reporting to FDA (B) is the sponsor's role. Sharing subject contact with sponsor (D) would violate confidentiality.
Correct answer:C.
References:
ICH E6(R2), §4.8.2.
21 CFR 50.25(b)(5).
insert code

Question 3

In accordance with 21 CFR Part 11, a closed electronic records system must do all EXCEPT:

Correct Answer: D
* 21 CFR 11.10:Requires validation, audit trails, secure access, but does not mandate printing capability.
Thus, (D) is the exception.
References:21 CFR 11.10.
insert code

Question 4

Which of the following identifies content that should be included in a clinical research protocol?

Correct Answer: D
Theprotocolmust provide scientific rationale, including prior nonclinical findings that justify human research.
* ICH E6(R2) 6.2.2:"The protocol should include... a summary of findings from nonclinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial." Other listed options belong elsewhere:
* IRB approvals (A) are separate administrative records.
* SOPs for data collection (B) are sponsor-level procedural documents.
* Investigator selection (C) is a sponsor's responsibility, not protocol content.
Thus, the correct answer isD (Summary of nonclinical findings with clinical relevance).
References:
ICH E6(R2), §6.2.2 (Protocol contents).
insert code

Question 5

A sponsor received a report from an investigator regarding the investigator's use of an investigational device without having obtained informed consent. The sponsor must submit a copy of the report to the FDA within:

Correct Answer: B
Informed consent is a fundamental ethical requirement. If it is violated in a device trial, the FDA requires rapid reporting.
* 21 CFR 812.150(b)(5):States that a sponsor shall submit to FDA "any report of use of a device without obtaining informed consent, within5 working daysafter the sponsor first receives notice of such use."
* This expedited reporting ensures FDA oversight of serious violations and protection of human subjects.
Incorrect options:
* A (1 day) is overly strict and not codified.
* C (10 days) and D (30 days) are too delayed to meet regulatory intent of immediate oversight.
Thus, the correct timeline iswithin 5 working days.
References:
21 CFR 812.150(b)(5).
insert code
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • »
  • »»
[×]

Download PDF File

Enter your email address to download SOCRA.CCRP.v2025-12-08.q47 Dumps

Email:

FreeQAs

Our website provides the Largest and the most Latest vendors Certification Exam materials around the world.

Using dumps we provide to Pass the Exam, we has the Valid Dumps with passing guranteed just which you need.

  • DMCA
  • About
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
©2025 FreeQAs

www.freeqas.com materials do not contain actual questions and answers from Cisco's certification exams.